Evogene Stock (NASDAQ:EVGN), Trade Ideas

Evogene

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.

pepi-stojanovski-MJSFNZ8BAXw-unsplash

Cannabis

Earnings

News

EVGN

Evogene Ltd. released its fourth-quarter and full-year 2023 financial results, showing a 237% revenue increase for the year. Despite a 12% revenue decrease in Q4, the Israeli cannabis company reported $5.6 million in total revenue for the year. CEO Ofer Haviv highlighted the company&#39;s successful collaborations with industry leaders like Corteva, ICL, and Syngenta, contributing to revenue growth. In Q4, gross profit decreased to $180,000, but net financing income rose to $287,000. Total operating expenses increased to $7.8 million, leading to a net loss of $7.3 million. For the full year, gross profit reached $3.9 million, and net financing income was approximately $521,000. Evogene also secured partnerships with Verb Biotics and Colors Farm, along with receiving a €1.2 million EU grant for its Ag-Seed Division&#39;s research and development efforts.

Israeli Company Reports Record 2023 Revenue, Wants To Transition Cannabis Operations To &#39;Third Party&#39;

rick-proctor-PGc9Vid8O24-unsplash

Earnings Beats

Evogene reports a strong Q3 with $3.8M revenue and significant gross profit growth, showcasing resilience and innovation in cannabis tech.

Israeli Cannabis Company Reports Strong Q3 Despite Geopolitical Challenges

Penny Stocks

Evogene Ltd (NASDAQ: EVGN) shares are trading lower by 5.9% to $0.63 Thursday morning after the company received a letter from the Nasdaq indicating that the company is not in compliance with the minimum bid price rule.

Why Evogene Shares Are Moving

Evogene Ltd

Evogene Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) (TASE: EVGN) announced on Thursday its financial results for the fourth quarter and full-year period ending December 31, 2023.
In the fourth quarter revenues amounted to $578 000, down 12% year-over-year. However, the Rehovot, Israel-based <a href="https://www.benzinga.com/cannabis">cannabis</a> company reported $5.6 million in revenue for 2023, representing a year-over-year increase of 237% from $1.7 million in 2022.
&#8220;The Evogene Group has experienced a transformative year with industry perception of our technology and products translating into growing collaborations with world-leading companies," Ofer Haviv, Evogene&#8217;s president and CEO, said in a press release.
Haviv praised the company's "collaboration momentum" referring to forged partnerships with Corteva, ICL, Syngenta and Baye, to name a few, via its subsidiaries Casterra Ag Ltd., AgPlenus Ltd., Biomica Ltd., and Lavie Bio Ltd. 
"These efforts not only validate our contributions but also bolster our financial position through various revenue streams, reflected in today&#8217;s reported revenues," Haviv added.
As for its Canonic Ltd. subsidiary that develops medical cannabis products based on decoding plant genetics for optimized therapeutic effect., Evogene said its reducing its investment in it as a &#8220;response to challenging market conditions in the medical cannabis sector.&#8221;
The company also said that it&#8217;s in advanced discussions regarding the potential transfer of Canonic&#8217;s operations to a third party. 
However, the completion and terms of such a transfer remain uncertain, Evogene said.
See also: <a href="https://www.benzinga.com/markets/cannabis/23/11/35828206/israeli-cannabis-company-reports-strong-q3-despite-geopolitical-challenges">Israeli Cannabis Company Reports Strong Q3 Despite Geopolitical Challenges</a>
<h3 class="wp-block-heading">Q4 2023 Financial Highlights</h3>
<ul>
<li>Gross profit totaled $180 000, down from $296 000 in the prior year's period.</li>
<li>Net financing income amounted to approximately $ 287,000, an increase from approximately $ 6,000 in the same period the previous year.</li>
<li>Total operating expenses amounted to $7.8 million, up from roughly $4 million in the same quarter of last year.</li>
<li>Net loss amounted to $7.3 million, an increase from $3.8 million in the same quarter of last year.</li>
</ul>
<h3 class="wp-block-heading">FY 2023 Financial Highlights</h3>
<ul>
<li>Gross profit totaled $3.9 million, up from $ 766,000 in the prior year's period.</li>
<li>Net financing income totaled approximately $521 000, compared to net financing expenses of approximately $2.8 million in the same period in the previous year.</li>
<li>Total operating expenses amounted to $30.4 million, up from roughly $27.7 million in the same quarter of last year.</li>
<li>Net loss amounted to roughly $26 million, down from around $3o million in the same quarter of last year.</li>
</ul>
<h3 class="wp-block-heading">Evogene&#8217;s Main Accomplishments In 2023</h3>
<ul>
<li>Partnership with Verb Biotics</li>
<li>Collaboration with Colors Farm and Ben Gurion University</li>
<li>€1.2 million ($1.2 million) EU Grant for Ag-Seed Division to develop oil-seed crops with enhanced CO2 assimilation and drought tolerance.</li>
</ul>
Now read: <a href="https://www.benzinga.com/markets/cannabis/23/08/33894969/israeli-cannabis-co-reports-solid-q2-performance-nearing-growth-targets">Israeli Cannabis Co. Reports Solid Q2 Performance, Nearing Growth Targets</a>
<h3 class="wp-block-heading">EVGN Price Action</h3>
Evogene's shares traded 4.43% lower at $0.8875 per share during the pre-market session on Thursday morning. 
The <a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a> is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at <a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">The Diplomat Beach Resort</a> will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Get your tickets now on </a><a href="http://bzcannabis.com" target="_blank" rel="noreferrer noopener">bzcannabis.com</a><a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener"> – Prices will increase very soon!</a>

Israeli Company Reports Record 2023 Revenue, Wants To Transition Cannabis Operations To 'Third Party'

Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 85.71 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $578.00 thousand.

Evogene Q4 EPS $(0.13) Beats $(0.14) Estimate, Sales $578.00K Beat $500.00K Estimate

AFCG

ALIM

AMTX

AOUT

ARBE

ARCT

ARHS

ASLE

ASPS

AVGO

BBAI

BBCP

BILI

BITF

BNED

BURL

CHMI

CIEN

CINT

CLAR

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

COOK

COST

CTOS

DBVT

DLTH

DOCU

DOMO

DSGR

DXPE

ELUT

EOLS

EYPT

FCEL

FNKO

GEVO

GIFI

GRND

GRNT

GWRE

HBIO

ISDR

JYNT

LCTX

LMNR

LOCO

LUMO

LVRO

METC

MGNX

MKFG

MRVL

NAPA

NCSM

NDLS

NEPH

NINE

ONCT

ONCY

OPFI

OPTN

OWLT

PBPB

PHAT

PMTS

PRCH

PowerShares Dynamic Industrials Sector Portfolio

PROF

PRTS

PSFE

RDVT

REAX

REFR

RWAY

SDPI

SGHT

Earnings Scheduled For March 7, 2024

Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-07. Here's what investors need to know before the announcement.
Analysts estimate that Evogene will report an earnings per share (EPS) of $-0.14. 
Evogene bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.08, which was followed by a 0.67% increase in the share price the next day.
Here's a look at Evogene's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.16</td>
<td>-0.17</td>
<td>-0.16</td>
<td>-0.20</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.08</td>
<td>-0.17</td>
<td>-0.15</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>9.0%</td>
<td>-4.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709748113_0.png" alt="eps graph" />
<a href="https://www.benzinga.com/quote/EVGN/earnings">To track all earnings releases for Evogene visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evogene Earnings Preview

Health Care

General

CTVA

AgPlenus Achieves Milestone In Collaboration With Corteva To Develop Novel Herbicides

Casterra Ag Ltd., an integrated solutions company for growing castor seeds for bio-based industries, such as biofuels, biopolymers, and a subsidiary of Evogen Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>, TASE: EVGN)), is taking significant steps to strengthen its castor production capabilities. The company recently signed strategic agreements with existing and new seed producers in Brazil and Africa to increase its production capabilities of high-yielding, highoil castor seeds. These agreements are expected to add approximately 400 tons in 2024 and establish long-term production infrastructure. Expanding the number of seed producers in various geographies with whom the company currently works is expected to lower production risks.

Contracts

Casterra Announced New Agreements With Seed Producers in Brazil And Africa To Meet Growing Demand ForIts Elite Castor Seed Varieties

Syngenta Crop Protection, a leader in agricultural innovation, and&nbsp;Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of&nbsp;Evogene Ltd.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) (TASE: EVGN), today announced an agreement for the discovery and development of new biological insecticidal solutions. The collaboration will leverage&nbsp;Lavie Bio&#39;s&nbsp;unique technology platform to rapidly identify and optimize bio-insecticide candidates, as well as Syngenta&#39;s extensive global research, development and commercialization capabilities.

Syngenta and Evogene Ltd Subsidiary, Lavie Bio Announce Partnership to Discover and Develop Novel Bio-Insecticide

Evogene Ltd.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across multiple market segments, and&nbsp;Verb Biotics LLC., a microbiome health ingredient company whose mission is to improve human health, entered into a collaboration agreement that will focus on the development of new strains of probiotic bacteria, which produce a highly sustainable quantity of microbial metabolites that improve human health and vitality. The collaboration will focus on identifying and enhancing the currently unknown genetic pathways in microbes that support the production of novel metabolites, using Evogene&#39;s&nbsp;MicroBoost AI&nbsp;tech-engine and Verb Biotics&#39; extensive accumulated knowledge in the field of the microbiome.

Evogene and Verb Biotics Enter Collaboration Agreement to Advance Probiotic Innovation, Financial Terms Undisclosed

Evogene Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>), a leading Israeli computational biology company, announced its financial results for the quarter ending September 30, 2023.
<h4 class="wp-block-heading">Q3 2023 Financial Highlights</h4>
<ul>
<li>Revenue for the third quarter of 2023 was $3.8 million, a notable increase compared to the $466 thousand in the same period of 2022.</li>
<li>Net loss reported for Q3 2023 was $3.9 million.</li>
<li>Gross profit significantly increased to $3.3 million compared to the $346 thousand in Q3 2022.</li>
<li>Adjusted EBITDA for this quarter was not reported by the company.</li>
</ul>
<a href="https://www.benzinga.com/quote/EVGN/news" target="_blank" rel="noreferrer noopener">Evogene</a>&#8216;s Q3 2023 revenues were approximately $3.8 million. The rise in revenues is attributed to Lavie Bio&#8217;s Corteva agreement and Casterra&#8217;s seed supply.
Operating loss decreased to approximately $4.2 million from $7.1 million last year, due to higher revenues. The net loss was reduced to about $3.9 million, a notable decrease compared to the $7.2 million in the same period of 2022.
Evogene&#8217;s president and CEO, Mr. Ofer Haviv, affirmed the company&#8217;s unwavering commitment to innovation and progress, underlining the financial stability of the Evogene Group.
<h4 class="wp-block-heading">Innovative Developments And Strong Financial Position</h4>
Evogene has been investing in collaborations to leverage its AI tech engines for medical <a href="https://www.benzinga.com/cannabis" target="_blank" rel="noreferrer noopener">cannabis</a> product development. Through Canonic Ltd, the group focused its marketing efforts on the frequent launching of new products in limited batches.
The group reported a consolidated cash position of approximately $37.2 million, with contributions from Lavie Bio, Biomica, and Evogene, including its subsidiaries Casterra, AgPlenus, and Canonic.
EVGN Price Action EVGN's shares were trading 1.15% lower at $0.65 per share at the time of this writing Thursday before the bell.
Photo by <a href="https://unsplash.com/@rickproctor?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener">Rick Proctor</a> on <a href="https://unsplash.com/photos/green-cannabis-plant-close-up-photography-PGc9Vid8O24?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener">Unsplash</a>

Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) reported its Q3 earnings results on Wednesday, November 15, 2023 at 07:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Evogene beat estimated earnings by 50.0%, reporting an EPS of $-0.08 versus an estimate of $-0.16.
Revenue was up $3.30 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.0 which was followed by a 8.59% increase in the share price the next day.
Here's a look at Evogene's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.17</td>
<td>-0.16</td>
<td>-0.20</td>
<td>-0.20</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.17</td>
<td>-0.15</td>
<td>-0.07</td>
<td>-0.16</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>880K</td>
<td>870K</td>
<td>420K</td>
<td>100K</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>654K</td>
<td>641K</td>
<td>660K</td>
<td>466K</td>
</tr>
</tbody>
</table>

To track all earnings releases for Evogene <a href="https://www.benzinga.com/quote/EVGN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Evogene Q3 Earnings

Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.16) by 50 percent. This is a 50 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $3.77 million which beat the analyst consensus estimate of $1.18 million by 219.24 percent. This is a 708.37 percent increase over sales of $466.00 thousand the same period last year.

Evogene Q3 EPS $(0.08) Vs $(0.16) YoY, Sales $3.77M Beat $1.18M Estimate

Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) is set to give its latest quarterly earnings report on Wednesday, 2023-11-15. Here's what investors need to know before the announcement.
Analysts estimate that Evogene will report an earnings per share (EPS) of $-0.16. 
Evogene bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 8.59% increase in the share price the next day.
Here's a look at Evogene's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.17</td>
<td>-0.16</td>
<td>-0.20</td>
<td>-0.20</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.17</td>
<td>-0.15</td>
<td>-0.07</td>
<td>-0.16</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.59%</td>
<td>-4.0%</td>
<td>-2.91%</td>
<td>-2.81%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1699977695_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Evogene were trading at $0.607 as of November 13. Over the last 52-week period, shares are down 14.63%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/EVGN/earnings">To track all earnings releases for Evogene visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Evogene's Earnings

<h3>Upgrades</h3>
For Invitation Homes Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the second quarter, Invitation Homes had an EPS of $0.44, compared to year-ago quarter EPS of $0.42. The stock has a 52-week-high of $36.53 and a 52-week-low of $28.52. At the end of the last trading period, Invitation Homes closed at $31.69. 
For Xylem Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>), Melius Research upgraded the previous rating of Hold to Buy. In the second quarter, Xylem showed an EPS of $0.98, compared to $0.66 from the year-ago quarter. The current stock performance of Xylem shows a 52-week-high of $118.58 and a 52-week-low of $84.16. Moreover, at the end of the last trading period, the closing price was at $91.03. 
According to DA Davidson, the prior rating for Clorox Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) was changed from Neutral to Buy. In the fourth quarter, Clorox showed an EPS of $1.67, compared to $0.93 from the year-ago quarter. At the moment, the stock has a 52-week-high of $178.21 and a 52-week-low of $124.59. Clorox closed at $131.06 at the end of the last trading period. 
BTIG upgraded the previous rating for LGI Homes Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) from Sell to Neutral. For the second quarter, LGI Homes had an EPS of $2.25, compared to year-ago quarter EPS of $5.20. The stock has a 52-week-high of $141.91 and a 52-week-low of $74.61. At the end of the last trading period, LGI Homes closed at $99.49. 
Morgan Stanley upgraded the previous rating for United States Steel Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) from Equal-Weight to Overweight. In the second quarter, United States Steel showed an EPS of $1.92, compared to $3.86 from the year-ago quarter. The current stock performance of United States Steel shows a 52-week-high of $32.68 and a 52-week-low of $18.02. Moreover, at the end of the last trading period, the closing price was at $32.48. 
According to Susquehanna, the prior rating for FedEx Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) was changed from Neutral to Positive. In the first quarter, FedEx showed an EPS of $4.55, compared to $3.44 from the year-ago quarter. The stock has a 52-week-high of $270.95 and a 52-week-low of $147.33. At the end of the last trading period, FedEx closed at $264.92. 
For Rivian Automotive Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. Rivian Automotive earned $1.08 in the second quarter, compared to $1.62 in the year-ago quarter. The current stock performance of Rivian Automotive shows a 52-week-high of $37.38 and a 52-week-low of $11.68. Moreover, at the end of the last trading period, the closing price was at $24.28. 
According to Piper Sandler, the prior rating for Zscaler Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) was changed from Neutral to Overweight. Zscaler earned $0.64 in the fourth quarter, compared to $0.25 in the year-ago quarter. The stock has a 52-week-high of $185.90 and a 52-week-low of $84.93. At the end of the last trading period, Zscaler closed at $155.59. 
For Datadog Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>), Piper Sandler upgraded the previous rating of Neutral to Overweight. Datadog earned $0.36 in the second quarter, compared to $0.24 in the year-ago quarter. The stock has a 52-week-high of $118.02 and a 52-week-low of $61.34. At the end of the last trading period, Datadog closed at $91.09. 
According to Piper Sandler, the prior rating for Macerich Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) was changed from Underweight to Neutral. For the second quarter, Macerich had an EPS of $0.40, compared to year-ago quarter EPS of $0.46. The stock has a 52-week-high of $14.51 and a 52-week-low of $7.73. At the end of the last trading period, Macerich closed at $10.91. 
According to Jefferies, the prior rating for Insulet Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) was changed from Hold to Buy. Insulet earned $0.38 in the second quarter, compared to $0.06 in the year-ago quarter. At the moment, the stock has a 52-week-high of $335.91 and a 52-week-low of $152.43. Insulet closed at $159.49 at the end of the last trading period. 
For Mr. Cooper Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>), Keefe, Bruyette &amp; Woods upgraded the previous rating of Market Perform to Outperform. For the second quarter, Mr. Cooper Gr had an EPS of $1.66, compared to year-ago quarter EPS of $0.17. The current stock performance of Mr. Cooper Gr shows a 52-week-high of $60.68 and a 52-week-low of $37.54. Moreover, at the end of the last trading period, the closing price was at $53.56. 
According to Keefe, Bruyette &amp; Woods, the prior rating for PennyMac Financial Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) was changed from Market Perform to Outperform. PennyMac Financial Servs earned $1.11 in the second quarter, compared to $2.28 in the year-ago quarter. The current stock performance of PennyMac Financial Servs shows a 52-week-high of $82.92 and a 52-week-low of $41.90. Moreover, at the end of the last trading period, the closing price was at $66.60. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
<h3>Downgrades</h3>
For Sun Communities Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>), B of A Securities downgraded the previous rating of Buy to Neutral. In the second quarter, Sun Communities showed an EPS of $1.96, compared to $2.02 from the year-ago quarter. At the moment, the stock has a 52-week-high of $163.83 and a 52-week-low of $117.20. Sun Communities closed at $118.34 at the end of the last trading period. 
According to Stephens &amp; Co., the prior rating for Ncino Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) was changed from Overweight to Equal-Weight. For the second quarter, Ncino had an EPS of $0.09, compared to year-ago quarter EPS of $0.04. At the moment, the stock has a 52-week-high of $37.22 and a 52-week-low of $19.58. Ncino closed at $31.80 at the end of the last trading period. 
For Sandy Spring Bancorp Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SASR#NASDAQ">SASR</a>), DA Davidson downgraded the previous rating of Buy to Neutral. For the second quarter, Sandy Spring Bancorp had an EPS of $0.60, compared to year-ago quarter EPS of $0.98. The current stock performance of Sandy Spring Bancorp shows a 52-week-high of $38.92 and a 52-week-low of $19.47. Moreover, at the end of the last trading period, the closing price was at $21.43. 
For Norfolk Southern Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>), B of A Securities downgraded the previous rating of Buy to Neutral. In the second quarter, Norfolk Southern showed an EPS of $2.95, compared to $3.45 from the year-ago quarter. The stock has a 52-week-high of $261.58 and a 52-week-low of $194.05. At the end of the last trading period, Norfolk Southern closed at $196.93. 
Wells Fargo downgraded the previous rating for NextEra Energy Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) from Overweight to Equal-Weight. In the second quarter, NextEra Energy Partners showed an EPS of $0.53, compared to $2.61 from the year-ago quarter. At the moment, the stock has a 52-week-high of $81.07 and a 52-week-low of $29.02. NextEra Energy Partners closed at $29.70 at the end of the last trading period. 
JP Morgan downgraded the previous rating for Chubb Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) from Overweight to Neutral. For the second quarter, Chubb had an EPS of $4.92, compared to year-ago quarter EPS of $4.20. The current stock performance of Chubb shows a 52-week-high of $231.37 and a 52-week-low of $178.08. Moreover, at the end of the last trading period, the closing price was at $208.18. 
Barclays downgraded the previous rating for SolarEdge Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from Overweight to Equal-Weight. SolarEdge Technologies earned $2.62 in the second quarter, compared to $0.95 in the year-ago quarter. The stock has a 52-week-high of $345.80 and a 52-week-low of $125.26. At the end of the last trading period, SolarEdge Technologies closed at $129.51. 
For Bread Financial Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>), Goldman Sachs downgraded the previous rating of Neutral to Sell. Bread Finl Hldgs earned $1.27 in the second quarter, compared to $0.25 in the year-ago quarter. The current stock performance of Bread Finl Hldgs shows a 52-week-high of $44.52 and a 52-week-low of $23.19. Moreover, at the end of the last trading period, the closing price was at $34.20. 
According to Piper Sandler, the prior rating for Splunk Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPLK#NASDAQ">SPLK</a>) was changed from Overweight to Neutral. Splunk earned $0.71 in the second quarter, compared to $0.09 in the year-ago quarter. The stock has a 52-week-high of $147.14 and a 52-week-low of $65.00. At the end of the last trading period, Splunk closed at $146.25. 
Mizuho downgraded the previous rating for Toast Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) from Buy to Neutral. Toast earned $0.19 in the second quarter, compared to $0.11 in the year-ago quarter. At the moment, the stock has a 52-week-high of $27.00 and a 52-week-low of $15.77. Toast closed at $18.73 at the end of the last trading period. 
For Fidelity National Financial Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>), Keefe, Bruyette &amp; Woods downgraded the previous rating of Outperform to Market Perform. In the second quarter, Fidelity National Finl showed an EPS of $1.01, compared to $1.90 from the year-ago quarter. At the moment, the stock has a 52-week-high of $45.51 and a 52-week-low of $31.84. Fidelity National Finl closed at $41.30 at the end of the last trading period. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
<h3>Initiations</h3>
Benchmark initiated coverage on TKO Group Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>) with a Buy rating. The price target for TKO Group Holdings is set to $100.00. The stock has a 52-week-high of $106.16 and a 52-week-low of $80.43. At the end of the last trading period, TKO Group Holdings closed at $84.06. 
Argus Research initiated coverage on Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) with a Buy rating. The price target for Novo Nordisk is set to $110.00. For the second quarter, Novo Nordisk had an EPS of $0.63, compared to year-ago quarter EPS of $0.42. The stock has a 52-week-high of $100.88 and a 52-week-low of $49.78. At the end of the last trading period, Novo Nordisk closed at $90.94. 
Wedbush initiated coverage on Etsy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Neutral rating. The price target for Etsy is set to $70.00. In the second quarter, Etsy showed an EPS of $0.93, compared to $0.51 from the year-ago quarter. The current stock performance of Etsy shows a 52-week-high of $149.91 and a 52-week-low of $61.22. Moreover, at the end of the last trading period, the closing price was at $64.58. 
Alliance Global Partners initiated coverage on AcelRx Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRX#NASDAQ">ACRX</a>) with a Buy rating. The price target for AcelRx Pharmaceuticals is set to $4.25. In the second quarter, AcelRx Pharmaceuticals showed an EPS of $0.40, compared to $1.20 from the year-ago quarter. The stock has a 52-week-high of $4.80 and a 52-week-low of $0.55. At the end of the last trading period, AcelRx Pharmaceuticals closed at $0.58. 
With a Buy rating, Alliance Global Partners initiated coverage on Evogene Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>). The price target seems to have been set at $1.85 for Evogene. In the second quarter, Evogene showed an EPS of $0.17, compared to $0.21 from the year-ago quarter. The stock has a 52-week-high of $1.44 and a 52-week-low of $0.55. At the end of the last trading period, Evogene closed at $0.59. 
TD Cowen initiated coverage on BigBear.ai Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) with a Market Perform rating. The price target for BigBear.ai Hldgs is set to $2.00. For the second quarter, BigBear.ai Hldgs had an EPS of $0.12, compared to year-ago quarter EPS of $0.17. The stock has a 52-week-high of $6.77 and a 52-week-low of $0.58. At the end of the last trading period, BigBear.ai Hldgs closed at $1.51. 
For Marathon Digital Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>), Needham initiated coverage, by setting the current rating at Hold. In the second quarter, Marathon Digital Holdings showed an EPS of $0.13, compared to $2.28 from the year-ago quarter. The current stock performance of Marathon Digital Holdings shows a 52-week-high of $19.88 and a 52-week-low of $3.12. Moreover, at the end of the last trading period, the closing price was at $8.50. 
Barclays initiated coverage on Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) with an Overweight rating. The price target for Credo Technology Group is set to $18.00. Credo Technology Group earned $0.03 in the first quarter, compared to $0.03 in the year-ago quarter. The current stock performance of Credo Technology Group shows a 52-week-high of $19.46 and a 52-week-low of $7.20. Moreover, at the end of the last trading period, the closing price was at $15.25. 
Mizuho initiated coverage on SunOpta Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKL#NASDAQ">STKL</a>) with a Buy rating. The price target for SunOpta is set to $9.00. In the second quarter, SunOpta showed an EPS of $0.03, compared to $0.03 from the year-ago quarter. At the moment, the stock has a 52-week-high of $11.67 and a 52-week-low of $3.33. SunOpta closed at $3.37 at the end of the last trading period. 
With a Buy rating, Ascendiant Capital initiated coverage on 60 Degrees Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>). The price target seems to have been set at $2.40 for 60 Degrees. 60 Degrees earned $1.40 in the second quarter, compared to $0.96 in the year-ago quarter. The current stock performance of 60 Degrees shows a 52-week-high of $8.65 and a 52-week-low of $0.67. Moreover, at the end of the last trading period, the closing price was at $0.74. 
UBS initiated coverage on Maxeon Solar Technologies Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) with a Neutral rating. The price target for Maxeon Solar Technologies is set to $13.00. Maxeon Solar Technologies earned $0.03 in the second quarter, compared to $2.15 in the year-ago quarter. The current stock performance of Maxeon Solar Technologies shows a 52-week-high of $38.91 and a 52-week-low of $11.30. Moreover, at the end of the last trading period, the closing price was at $11.59. 
With a Buy rating, UBS initiated coverage on Sunnova Energy International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>). The price target seems to have been set at $16.00 for Sunnova Energy Intl. In the second quarter, Sunnova Energy Intl showed an EPS of $0.74, compared to $0.32 from the year-ago quarter. The current stock performance of Sunnova Energy Intl shows a 52-week-high of $24.81 and a 52-week-low of $9.87. Moreover, at the end of the last trading period, the closing price was at $10.47. 
With a Neutral rating, UBS initiated coverage on Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>). The price target seems to have been set at $225.00 for Atlassian. Atlassian earned $0.57 in the fourth quarter, compared to $0.27 in the year-ago quarter. The current stock performance of Atlassian shows a 52-week-high of $246.15 and a 52-week-low of $113.86. Moreover, at the end of the last trading period, the closing price was at $201.51. 
With a Neutral rating, UBS initiated coverage on Datadog Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>). The price target seems to have been set at $100.00 for Datadog. In the second quarter, Datadog showed an EPS of $0.36, compared to $0.24 from the year-ago quarter. The stock has a 52-week-high of $118.02 and a 52-week-low of $61.34. At the end of the last trading period, Datadog closed at $91.09. 
UBS initiated coverage on NEXTracker Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Buy rating. The price target for NEXTracker is set to $50.00. At the moment, the stock has a 52-week-high of $46.55 and a 52-week-low of $28.24. NEXTracker closed at $40.16 at the end of the last trading period. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Upgrades

Downgrades

Initiation

Intraday Update

Analyst Ratings

ACRX

COOP

CRDO

DDOG

ETSY

INVH

LGIH

MARA

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

NCNO

NOVA

PFSI

PODD

RIVN

SASR

SEDG

SPLK

STKL

SXTP

TEAM

TOST

Benzinga's Top Ratings Upgrades, Downgrades For October 2, 2023

Alliance Global Partners analyst Ben Haynor initiates coverage on Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) with a Buy rating and announces Price Target of $1.85.

Price Target

Alliance Global Partners Initiates Coverage On Evogene with Buy Rating, Announces Price Target of $1.85

Casterra Ag Ltd. (&quot;Casterra&quot;), an integrated castor cultivation solution company and a subsidiary of&nbsp;Evogene Ltd.&nbsp;(&quot;Evogene&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) (TASE: EVGN), today announced the shipment of its first batch of high-yield, high-oil castor seeds from&nbsp;Brazil&nbsp;and&nbsp;Zambia&nbsp;to its destination in&nbsp;Africa. This shipment, valued at&nbsp;US$1 million, is the first step in meeting&nbsp;US$11.3M&nbsp;purchase orders from a world-leading oil and gas company, which Casterra received in the&nbsp;second quarter&nbsp;of 2023.

Casterra Delivers First Shipment of Castor Seeds to Africa

Evogene Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evgn#NASDAQ">EVGN</a>)&nbsp;shares are trading lower by 5.9% to $0.63 Thursday morning after the company received a letter from the Nasdaq indicating that the company is not in compliance with the <a href="https://www.benzinga.com/quote/EVGN/news">minimum bid price rule</a>.
If Evogene&nbsp;does not demonstrate compliance prior to the end of the 180-day period ending March 18, 2024, the Nasdaq&rsquo;s staff will notify the company that its ordinary shares will be subject to delisting.
Evogene says the company is emphasizing the importance of staying listed on Nasdaq. If their stock price doesn&#39;t improve within a certain timeframe, Evogene says the company&nbsp;open to exploring <a href='https://www.benzinga.com/money/best-options-to-buy-this-week/'>options</a> to address this issue, including the possibility of a reverse share split.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, EVGN&nbsp;has a 52-week high of $1.44 and a 52-week low of $0.55.

WIIM

Evogene shares are trading lower after the company received a letter from the Nasdaq indicating that the company is not in compliance with the minimum bid price rule.

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

<a href="https://patentcenter.uspto.gov/applications/16613968/ifw/docs" title="https://patentcenter.uspto.gov/applications/16613968/ifw/docs">https://patentcenter.uspto.gov/applications/16613968/ifw/docs</a>

Legal

Evogene Receives Notice Of Allowance For U.S. Patent Titled 'BIOMARKERS AND METHODS FOR DETECTION OF SEIZURES AND EPILEPSY'

Lake Street has decided to maintain its Buy rating of Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) and raise its price target from $2.00 to $3.00.
Shares of Evogene are trading up 1.01% over the last 24 hours, at $0.64 per share.
A move to $3.00 would account for a 368.09% increase from the current share price.
<h3>About Evogene</h3>
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment.
<h3>About Analyst Ratings</h3>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Lake Street Maintains Buy Rating for Evogene: Here's What You Need To Know

Evogene Ltd (EVGN) surpassed earnings projections on 3/7/2024 for Q4 2023.Evogene Ltd Ord's earnings came in at an EPS loss of $0.13 per share, 7.00% higher than estimates for an EPS loss of $0.14 per share. The firm's loss per share expanded by 86% since reporting a loss of $0.07 per share a year ago. Revenues were downbe

Evogene Ltd Ord Down 2.02% To $0.91 After Earnings Beat

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Evogene (NASDAQ:<a href="https://investorplace.com/stock-quotes/evgn-stock-quote/">EVGN</a>) just reported results for the fourth quarter of 2023.<ul><li>Evogene reported earnings per share of -13 cents. This was above the analyst estimate for EPS of -14 cents.</li><li>The company reported revenue of $578,000.</li><li>This was 36.48% worse than the analyst estimate for revenue of $910,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/evgn-stock-earnings-evogene-for-q4-of-2023/">EVGN Stock Earnings: Evogene Beats EPS, Misses Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EVGN Stock Earnings: Evogene Beats EPS, Misses Revenue for Q4 2023

Evogene Ltd. (EVGN) Q4 2023 Earnings Call Transcript

Evogene gets non-compliance notice from Nasdaq

Evogene Ltd. (EVGN) has released an update. Evogene Ltd., a leading computational biology company, has received a notification from Nasdaq indicati...

Evogene Ltd. Faces Nasdaq Compliance Challenge

Overall market sentiment has been neutral on Evogene Ltd (EVGN)  stock lately. EVGN receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator. Evogene Ltd has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on EVGN!See Full EVGN ReportWhat is Stock Sentiment?W

Is Evogene Ltd (EVGN) Stock About to Get Hot Tuesday?

Evogene Ltd. (EVGN) has released an update. Evogene Ltd., an Israeli biotech firm, has entered into a sales agreement with Lake Street Capital Mark...

Evogene Ltd. Announces $7.3 Million Share Sale Plan

In a report released today, Ben Klieve from Lake Street maintained a Buy rating on Evogene (EVGN – Research Report), with a price target of $3.00. ...

Evogene (EVGN) Receives a Buy from Lake Street

Evogene Ltd. (EVGN) has released an update. Evogene Ltd. and The Kitchen FoodTech Hub by Strauss Group have co-founded Finally Foods Ltd., a compan...

Evogene's New Venture Targets Sustainable Protein Market

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evogene (EVGN – Research Report), Edwards Lifescienc...

Analysts Offer Insights on Healthcare Companies: Evogene (EVGN), Edwards Lifesciences (EW) and Nurix Therapeutics (NRIX)

NRIX

Press Releases

Casterra Announces New Agreements with Seed Producers in Brazil and Africa to Meet Growing Demand for its Elite Castor Seed Varieties

AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides

Evogene Reports Fourth Quarter and Full Year 2023 Financial Results

Lavie Bio and Ceres Global Ag Corp. Collaborate to Include YalosTM Bio-Inoculant, in Regenerative Agriculture Initiatives in North America

Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing

Small Cap

Evogene Announces Filing of Annual Report on Form 20-F

Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry

Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting

Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting